Evidence map›Paper›PMID 31746105›Full record

ArticleEMBO molecular medicine2020

Live vaccines-a short-cut to cancer viro-immunotherapy.

Thomas C Wirth, Julia Niemann, Florian Kühnel

Abstract readComment
In one paragraph

Article in EMBO molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Thomas C WirthDeparment of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany.
Julia NiemannDeparment of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany.
Florian KühnelDeparment of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany.ORCID 0000-0001-6942-1573

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumour immunotherapies have been a breakthrough in clinical oncology but only a few patients benefit from this progress. Additional interventions that sensitize immunologically cold tumours for the administration of checkpoint modifiers are urgently needed. In this issue of EMBO Molecular Medicine, Aznar et al present the already approved yellow fever vaccine 17D as an oncolytic agent for tumour immunoactivation. In tumour-bearing mice, they demonstrated a convincing synergy of the vaccine with CD137 agonistic antibodies resulting in significantly improved survival.

Indexed as

NeoplasmsYellow Fever VaccineAnimalsHumansImmunotherapyMiceVaccines, AttenuatedVaccines, AttenuatedYellow Fever Vaccine

Identifiers

PMID31746105
PMCPMC6949510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.